Pharma BD Deal Intelligence
A $20M all-stock deal that ended with the entire combined R&D portfolio—including the AdProTech complement-inhibition platform it was meant to showcase—sold off for just $4M cash three years later. Inflazyme's own legacy asthma drug failed Phase IIb, triggering a 71.5% stock collapse and company wind-down.
Value destroyed: $20M all-stock deal ended with the entire combined R&D portfolio sold for $4M cash three years later, followed by company wind-down
Full analysis, sources & comparables →Inflazyme exchanged 12,684,055 common shares for AdProTech, valued at ~C$20M, gaining a complement-inhibition platform, a Phase IIa rheumatoid arthritis asset,…
Inflazyme cuts jobs after drug trial failure — within ~18 months of the AdProTech acquisition, the combined entity faced clinical setbacks that triggered…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
April 2004; 12.7M Inflazyme shares; UK biotech; complement system inhibitors; ex-GSK spinout
Value destroyed: $20M all-stock deal ended with the entire combined R&D portfolio sold for $4M cash three years later, followed by company wind-down
Assessment window: 15yr post-close.
Rheumatoid arthritis is a chronic autoimmune disease characterized by inflammatory synovitis, joint destruction, and systemic complications, affecting roughly 1.3 million US adults (~0.5% prevalence per 2004-2014 healthcare claims data). Complement system activation is a downstream amplifier of RA inflammation; AdProTech's APT070 (Mirococept) program targeted local complement inhibition via direct intra-articular injection.
By 2004, the RA market had been transformed by TNF-alpha biologics: Abbott's Humira (FDA 2002), Amgen/Wyeth's Enbrel (FDA 1998), and J&J/Schering-Plough's Remicade (FDA 1999) commanded the front-line biologic segment, with Roche's Rituxan and Bristol's Abatacept (Orencia, approved 2005) emerging as second-line options. AdProTech's APT070 took a fundamentally different angle — a truncated recombinant human complement receptor-1 (sCR1) anchored by AdProTech's Prodaptin membrane-targeting tag, delivered intra-articularly to inhibit complement at the site of inflammation rather than systemically blocking TNF (per BioWorld and AdisInsight). At time of the deal, APT070 was in a 45-patient Phase IIa knee-injection study, with parallel programs in transplant ischemia-reperfusion (Mirococept later licensed to Imperial College for the EMPIRIKAL kidney transplant trial). Inflazyme — fresh off the failure of its lead asthma asset LSAID — paid C$20M (~US$15M) in 12.7M shares plus C$7M assumed cash to acquire AdProTech (an ex-SmithKline Beecham 1997 spinout) to rebuild its pipeline around inflammation. The deal did not rescue Inflazyme; subsequent program failures led to staff cuts and eventual asset divestiture. Source: https://www.bioworld.com/articles/468169
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Inflazyme Pharmaceuticals Ltd. / AdProTech Limited (this deal) | 2004 | $20M | 8 |
| UCB SA / Celltech Group plc | 2004 | $2.7B | 92 |
| Yamanouchi Pharmaceutical / Fujisawa Pharmaceutical Co. Ltd. | 2004 | $7.6B | 84 |
| Abbott Laboratories / TheraSense Inc. | 2004 | $1.2B | 81 |
| Sanofi-Synthelabo SA / Aventis SA | 2004 | $65.0B | 80 |
| Genzyme Corporation / ILEX Oncology Inc. | 2004 | $1.0B | 66 |
| Hospira Inc. / Abbott Hospital Products Division | 2004 | — | 54 |
← Browse all deals · How we score deals
More: 2004 deals